BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead…
-
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they…
-
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene…
-
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera…
-
Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy
Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.…
-
FDA approves UCB’s Kygevvi for genetic mitochondrial disease
The US Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic mitochondrial disease, thymidine…
-
Eli Lilly to invest $3bn in new Dutch manufacturing facility
Eli Lilly and Company has outlined plans to develop a $3bn manufacturing facility in Katwijk, situated in the Leiden Bio…
-
IntoCell and Xcellon Biologics to advance ADC development
South Korean biotechnology company IntoCell has announced a memorandum of understanding (MoU) with US-based contract development and manufacturing organisation (CDMO)…
-
4DMT and Otsuka to advance eye disease treatment in APAC
4D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment…